Quick Answer
GRI Bio, Inc. reported Cash and Equivalents of $8.23 million for fiscal year 2025.
GRI Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.23M | +63.7% |
| 2024 | $5.03M | +178.1% |
| 2023 | $1.81M | +19988.9% |
| 2022 | $9.0K | -99.8% |
| 2021 | $3.70M | +3296.3% |
| 2020 | $109.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.05M | -14.6% | -20.8% |
| June 30, 2025 | $5.12M | -19.4% | +56.1% |
| March 31, 2025 | $3.28M | -19.8% | -34.7% |
| December 31, 2024 | $5.03M | +178.1% | +5.9% |
| September 30, 2024 | $4.75M | +36.1% | -25.3% |
| June 30, 2024 | $6.35M | +32.4% | +55.3% |
| March 31, 2024 | $4.09M | +145.7% | +126.3% |
| December 31, 2023 | $1.81M | +19988.9% | -48.2% |
- GRI Bio, Inc. showed an increase of +63.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, GRI Bio, Inc.’s cash and equivalents has grown by 7449.5% (from $109.0 thousand to $8.23 million).
- The most recent figure is from GRI Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: